Hence, current clinical guidelines for HCC recommend initiating antiviral therapy in liver cirrhosis patients regardless of ALT levels and in CHB patients with significant liver fibrosis despite ALT being less than two times the upper limit of normal [33,36]. This evidence concerns the gene GPT and Hepatic fibrosis.